articleThe Lancet OncologyJun 24, 2015BRONZE OA

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

ARAntoni RibasIPIgor PuzanovRDReinhard DummerDSDirk SchadendorfOHOmid Hamid

University of California, Los Angeles · Vanderbilt University · +32 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,560
total citations
FWCI
107.96
Percentile
100%
References
32
Citations per year

Authors

36

Topics & keywords

Topics
Keywords
  • Medicine
  • Ipilimumab
  • Pembrolizumab
  • Internal medicine
  • Carboplatin
  • Clinical endpoint
  • Adverse effect
  • Dacarbazine
No related works found for this paper.